HYB 190

Drug Profile

HYB 190

Alternative Names: HYB-190; PKAI-AS 190

Latest Information Update: 23 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idera Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides; Nucleotides
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Renal cancer

Most Recent Events

  • 31 Mar 2006 Discontinued - Preclinical for Renal cancer in USA (unspecified route)
  • 28 May 2001 No-Development-Reported for Renal cancer in USA (Unknown route)
  • 05 Nov 1998 Preclinical development for Renal cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top